Ophthalmic antibiotic use for acute infectious conjunctivitis in children


Posted: 2021-11-05 19:00:00
Background: Infectious conjunctivitis is among the most common pediatric infections worldwide; antibiotics are often not indicated. We aimed to determine factors associated with ophthalmic antibiotic prescribing and changes in prescribing prior to and during the COVID-19 pandemic at a single center. Methods: Encounters for children with infectious conjunctivitis from 2017 to 2020 at Denver Health and Hospital Authority clinics were analyzed retrospectively. Factors associated with prescribing were evaluated using multivariable logistic regression modeling. Encounter numbers and prescribing patterns for telephone versus in-person visits before and during the pandemic were compared and stratified. Results: Of 5,283 patients encounters for conjunctivitis, 3,841 (72.7%) resulted in an ophthalmic antibiotic prescription. Concurrent diagnosis with acute otitis media (adjusted odds ratio [aOR] 0.20 (95% CI, 0.16-0.25) and later study year (2018-aOR = 0.76 [95% CI, 0.65-0.89]; 2019- aOR = 0.57 [95% CI, 0.48-0.67]) were associated with reduced odds of prescribing. Compared with those evaluated in pediatric clinics, patients evaluated in family medicine (aOR = 0.69 [95% CI, 0.58-0.83]) or optometry/ophthalmology clinics (aOR = 0.06 [95% CI, 0.02-0.14]) were less likely to have antibiotics prescribed, whereas, patients evaluated via telephone had a 5.43 (95% CI, 3.97-7.42) greater odds of being prescribed ophthalmic antibiotics. Antibiotic prescribing increased from 67.8% prior to the COVID-19 pandemic to 81.9% during the pandemic (P < 0.0001). Conclusions: Discordant with national guideline recommendations, ophthalmic antibiotic use for conjunctivitis was high. Telephone visits were associated with higher rates of prescribing. Rates of prescribing increased significantly during the COVID-19 pandemic.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
5月 11, 2020 バイオアソシエイツ

COVID-19治療薬レロンリマブについてのQ&A、リファレンス

2020年5月1日CytoDyn社WEBINARにおけるレロンリマブに関する質問(ログインするとQ&Aを表示):• この薬は COVID-19 の単剤治療に使用できますか?それとも最終的な分析に役立つ併用薬物療法を想定していますか?• FDAがレロンリマブを使用することで何人の命を救うことができるのかを理解するのが難しいのはなぜですか?• レロンリマブは、主に免疫系の回復または何らかの新しいメカニズムによる血漿ウイルス負荷を軽減する能力がありますか?•…

ゲスト 603人 と メンバー 6人 がオンラインです